A Possible Ebola Virus Vaccine Using Chimpanzee Adenovirus

In an animal study, the vaccine was completely protective against an acute lethal challenge; boosting it with modified vaccinia Ankara provided protection for ≥10 months.

Human adenovirus type 5 (rAd5) vectors have been extensively studied as vaccines against numerous pathogens. Such vaccines have been shown to confer protection against acute Ebola virus challenge. However, the use of human adenovirus vectors is restricted because of preexisting immunity to them. Adenoviruses isolated from nonhuman primates may overcome this limitation. In particular, chimpanzee adenoviruses (ChAds) have been found not to induce a human antibody response, and they have low worldwide seroprevalence.

A multinational team including individuals from the National Institute of Allergy and Infectious Diseases Okairos (a division of GlaxoSmithKline) recently identified a potential vector, ChAd3, based on its low neutralization by hum…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

A Possible Ebola Virus Vaccine Using Chimpanzee Adenovirus

Topics

Reviewing Author